Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14

Benzinga Newsdesk www.benzinga.com Negative 53.1%

Neg 53.1% Neu 0% Pos 0%

Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $15 to $14.